Fabtech technologies Limited has announced its participation in an investor interaction event scheduled for February 28, 2026, as part of CVOC A Investocraft 2026. The company has informed both the National Stock Exchange of India Limited and BSE Limited about this engagement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Meeting Details

The investor interaction is structured as a group meeting with investors and will be conducted in physical mode. The event details are as follows:

Regulatory Compliance

The company has emphasized its commitment to regulatory compliance by ensuring that all discussions during the meeting will be based on publicly available information only. Fabtech Technologies Limited has specifically stated that no unpublished price-sensitive information is intended to be shared or discussed during the investor interaction.

Meeting Coordination

The notification was signed by Hemant Mohan Anavkar, Executive Director with DIN: 00150776, on February 26, 2026. The company has noted that the meeting schedule was finalized and confirmed on the same day, resulting in shorter notice to the exchanges. Additionally, Fabtech Technologies Limited has indicated that the meeting schedule may undergo changes due to exigencies on part of the participants or the company.

This investor interaction represents part of the company's ongoing engagement with the investment community and adherence to transparency requirements under SEBI regulations.

Fabtech Technologies Limited has secured a major international contract worth USD 7.05 million from a West Africa-based company, as disclosed under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Contract Details

The company announced on February 14, 2026, that it has bagged this significant order for the supply, installation and commissioning of infrastructure for an Oral Solid Dosage (OSD) facility. The contract value stands at USD 7,050,000.00, which translates to approximately Rs. 63.6 crores.

Project Scope and Timeline

The contract encompasses a comprehensive agreement for the supply, installation and commissioning of infrastructure required for pharmaceutical manufacturing. The project is scheduled to be completed within 23-27 months from the date of receiving the advance payment from the client.

Confidentiality and Compliance

Due to confidentiality obligations, Fabtech Technologies has not disclosed the name of the West African client. The company has confirmed that this contract does not fall within related party transactions and that neither the promoter, promoter group, nor group companies have any interest in the entity that awarded the contract.

Strategic Significance

This international order represents a significant business development for Fabtech Technologies, demonstrating the company's capabilities in pharmaceutical infrastructure projects across global markets. The contract reinforces the company's position in the international pharmaceutical equipment and infrastructure sector, particularly in emerging markets like West Africa.